OcuSciences.com

Ann Arbor, United States Founded: 2008 • Age: 18 yrs
Retinal metabolic imaging is conducted using flavoprotein fluorescence technology.

About OcuSciences.com

OcuSciences.com is a Healthcare company based in Ann Arbor (United States) founded in 2008 by Victor Elner. Retinal metabolic imaging is conducted using flavoprotein fluorescence technology. OcuSciences.com has raised $25 thousand across 2 funding rounds from investors including Ann Arbor SPARK. OcuSciences.com offers products and services including Functional Retinal Imager. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Imaging. Its competitors include Inoveon, Diopsys and Bioptigen; 3 of its 3 listed competitors have raised funding.

Company details

OcuSciences is a medical diagnostic device company developing a patented non-invasive ocular imaging technique. The technique, Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma. Their offering, OcuMet Beacon, can help identify retinal metabolic diseases with its patented flavoprotein fluorescence (FPF) technology. OcuSciences was co-founded by Drs. Victor Elner and Howard Petty from the University of Michigan Kellogg Eye Center.

  • Headquarters Ann Arbor, United States
  • Founders Victor Elner
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website ocusciences.com
  • Social LinkedIn X
Operational Areas
Key Metrics
  • Total Equity Funding
    $25K (USD)

    in 2 rounds

  • Latest Funding Round
    $25K (USD), Seed

    May 2009

  • Investors

Products & Services of OcuSciences.com

OcuSciences.com offers a comprehensive portfolio of products and services, including Functional Retinal Imager.

Functional Retinal Imager
Medical Device

Device for imaging and diagnosing retinal conditions in healthcare.

Funding Insights of OcuSciences.com

OcuSciences.com has successfully raised a total of $25K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $25 thousand completed in May 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $25,000
  • Total Rounds 2
  • Last Round Seed β€” $25,000
  • First Round $25,000

    (Jun 2008)

  • Investors Count 1

All 2 funding rounds of OcuSciences.com with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2009$25,000Seed––
Jun 2008$25,000Grant––
–
Valuation history

1 investors in total: 1 institutional.

Investors in OcuSciences.com

OcuSciences.com has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Ann Arbor SPARK.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
annarborusa.org
Premium access

Investor details for OcuSciences.com

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of OcuSciences.com

4 people are tracked at OcuSciences.com (3 in leadership, 1 in team).

NameRoleGroup
Victor Elner
Co-FounderLeadership
Kurt Riegger
President/CEOLeadership
Collin Rich
CTOLeadership
Anthony Leithauser
Product EngineerTeam
Premium access

Complete people profiles for OcuSciences.com

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of OcuSciences.com

3 dated milestones of OcuSciences.com across 1 years, from founding to its latest funding, stage changes and deals.

  1. Founded OcuSciences.com is founded.
  2. Funding First funding round of $25K.
  3. Funding Latest funding round, Seed, of $25K.

Competitors of OcuSciences.com

OcuSciences.com has 3 listed competitors in our database, 3 of them funded. They include Inoveon, Diopsys and Bioptigen.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
inoveon.com1998Oklahoma, United States$16M10
Eye disease detection services including diabetic retinopathy are provided.
diopsys.com2002Montville, United States$1.05M31
Non-invasive visual electrophysiology devices are supplied for ophthalmological diagnosis.
bioptigen.com2004United States$2.79M25
Spectral domain OCT devices for ophthalmic imaging are developed.
Premium access

Detailed competitors of OcuSciences.com

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Ophthalmology

3 companies that operate in the same segment as OcuSciences.com (Ophthalmology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of a wide range of eye care products
1945Fort Worth, Texas, United StatesUSD 171.61 MUSD 9.64 B25,600
Genetic medicines are developed by 4DMT for transformative therapies.
2013Emeryville, California, United StatesUSD 186.59 MUSD 85.21 M227
Developer of antibodies to treat complement-mediated neurodegenerative diseases
2011San Francisco, California, United StatesUSD 256 M100
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ocusciences.Com

Premium access

Complete news archive for OcuSciences.com

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about OcuSciences.com

OcuSciences.com was founded in 2008.

OcuSciences.com is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.

OcuSciences.com is a funded company, having raised a total of $25K across 2 funding rounds to date. The company's 1st funding round was a Grant of $25K, raised on Jun 2008.

OcuSciences is a medical diagnostic device company developing a patented non-invasive ocular imaging technique. The technique, Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma. Their offering, OcuMet Beacon, can help identify retinal metabolic diseases with its patented flavoprotein fluorescence (FPF) technology. OcuSciences was co-founded by Drs. Victor Elner and Howard Petty from the University of Michigan Kellogg Eye Center.

OcuSciences.com's top competitors include Diopsys, Inoveon and Bioptigen.

OcuSciences.com offers Functional Retinal Imager.

OcuSciences.com has 1 investor. Key investors include Ann Arbor SPARK.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available